Maintenance Ruxolitinib

Phase II Study of Maintenance Ruxolitinib After Allogeneic Stem Cell Transplantation for Older Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) in Complete Remission

More Information

Trial Status
Accepting patients
Trial Phase
Phase 2
Enrollment
64 patients (estimated)
Sponsors
Massachusetts General Hospital
Collaborators
Washington University School of Medicine, Ohio State University Comprehensive Cancer Center, Medical College of Wisconsin, Vanderbilt University Medical Center
Tags
JAK2 Inhibitor, Tyrosine Kinase (TK) Inhibitor, Maintenance, Post-Allogeneic Stem Cell Transplant
Trial Type
Treatment
Last Update
3 months ago
SparkCures ID
1671
NCT Identifier
NCT03286530

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print this trial to share with your doctor.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.